Lv3
328 积分 2023-12-07 加入
Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management
7小时前
已关闭
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
1个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
3个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
6个月前
已完结
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes
6个月前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
8个月前
已完结
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
8个月前
已完结
The prostate cancer drug market
1年前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1年前
已完结
IgA nephropathy
1年前
已完结
皖公网安备34019202002308
